Moreover, Hanker et al. [48] proposed that the combination of HER2 and FGFR inhibitors be studied prospectively in HER2+ breast cancer patients with somatic alterations of the FGFR pathway. The gene discussed is ERBB2; the disease is breast carcinoma.